Shinsan M. Su

13.5k citations

16 papers · 6.9k indexed · 3 hit papers · h-index 13

Molecular Biology top 1%
Cancer Research top 0.2%
Genetics top 0.2%
Hematology top 0.5%
Oncology top 5%

Co-authors: Lenny Dang Valeria R. Fantin Shengfang Jin Katharine Yen Patrick S. Ward Joshua D. Rabinowitz Bryson D. Bennett Craig B. Thompson
Topics: Cancer, Hypoxia, and Metabolism (11 papers)Glioma Diagnosis and Treatment (9 papers)Epigenetics and DNA Methylation (6 papers)
Cited by: Cancer Research Genetics Hematology
Journals: Nature The Journal of Experimental Medicine Genes & Development
Partner nations: United States Canada China

In The Last Decade

Shinsan M. Su

16 papers receiving 6.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

2009 3.1k citations Lenny Dang, David W. White et al. Nature profile →
The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate

2010 1.5k citations Patrick S. Ward, Jay Patel et al. Cancer Cell profile →
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

2010 558 citations Stefan Größ, Rob A. Cairns et al. The Journal of Experimental Medicine profile →

Peers

Countries citing papers authored by Shinsan M. Su

Since Specialization

Citations

This map shows the geographic impact of Shinsan M. Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shinsan M. Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shinsan M. Su more than expected).

Fields of papers citing papers by Shinsan M. Su

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shinsan M. Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shinsan M. Su. The network helps show where Shinsan M. Su may publish in the future.

Co-authorship network of co-authors of Shinsan M. Su

This figure shows the co-authorship network connecting the top 25 collaborators of Shinsan M. Su. A scholar is included among the top collaborators of Shinsan M. Su based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shinsan M. Su. Shinsan M. Su is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies 2021 ·Drug Metabolism and Disposition ·Yue Chen,N. Nagaraja,Bin Fan,Luke Utley,René M. Lemieux,Janeta Popovici-Müller,Lenny Dang,Hyeryun Kim,Liping Yan,Shinsan M. Su,Scott A. Biller,Hua Yang	7
2	Abstract B126: AG-881, a brain penetrant, potent, pan-mutant IDH (mIDH) inhibitor for use in mIDH solid and hematologic malignancies 2018 ·Molecular Cancer Therapeutics ·Katharine Yen,Zenon Konteatis,Zhihua Sui,Erin Artin,Lenny Dang,Kimberly Straley,Erica R. Tobin,Carl Campos,Hua Yang,Raj Nagaraja,Yue Chen,Hyeryun Kim,Camelia Gliser,Brandon Nicolay,Andrew Olaharski,Lee Silverman,Scott A. Biller,Shinsan M. Su,Ingo K. Mellinghoff,Janeta Popovici-Müller	16
3	Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development 2017 ·Annual Review of Biochemistry ·Lenny Dang,Shinsan M. Su	161
4	A mouse model of a human congenital disorder of glycosylation caused by loss of PMM2 2016 ·Human Molecular Genetics ·Barden Chan,Michelle Clasquin,Gromoslaw A. Smolen,Gavin Histen,(unknown),Yue Chen,Zhi‐Zhong Lin,(unknown),Yan Liu,Yong Cang,(unknown),Yuanfeng Xia,(unknown),Chris Singleton,Marion Dorsch,Lee Silverman,Shinsan M. Su,Hudson H. Freeze,Shengfang Jin	33
5	Proto-Oncogenic Role of Mutant IDH2 in Leukemia Initiation and Maintenance 2014 ·Cell stem cell ·Lev M. Kats,Markus Reschke,Riccardo Taulli,Olga Pozdnyakova,Kerri Burgess,Parul Bhargava,Kimberly Straley,Rahul Karnik,Alexander Meissner,Donald Small,Shinsan M. Su,Katharine Yen,Jiangwen Zhang,Pier Paolo Pandolfi	146
6	IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition 2014 ·Blood ·Andrew Kernytsky,Fang Wang,Erica Hansen,Stefanie S. Schalm,Kimberly Straley,Camelia Gliser,Hua Yang,Jeremy Travins,Stuart Murray,Marion Dorsch,Sam Agresta,David P. Schenkein,Scott A. Biller,Shinsan M. Su,Wei Liu,Katharine Yen	128
7	Abstract 2296: IDH2 mutation induced histone and DNA hypermethylation is progressively reversed by small molecule inhibition 2014 ·Cancer Research ·Andrew Kernytsky,Fang Wang,Erica Hansen,Stefanie S. Schalm,Kimberly Straley,Camelia Gliser,Hua Yang,Jeremy Travins,Stuart Murray,Marion Dorsch,Sam Agresta,David P. Schenkein,Scott A. Biller,Shinsan M. Su,Wei Liu,Katharine Yen	1
8	Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo 2012 ·ACS Medicinal Chemistry Letters ·Janeta Popovici-Müller,Jeffrey O. Saunders,Francesco G. Salituro,Jeremy Travins,Shunqi Yan,Fang Zhao,Stefan Größ,Lenny Dang,Katharine Yen,Hua Yang,Kimberly Straley,Shengfang Jin,Kaiko Kunii,Valeria R. Fantin,Shunan Zhang,(unknown),(unknown),Scott A. Biller,Shinsan M. Su	160
9	D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function 2012 ·Genes & Development ·Masato Sasaki,Christiane B. Knobbe‐Thomsen,Momoe Itsumi,Andrew Elia,Isaac S. Harris,Iok In Christine Chio,Rob A. Cairns,Susan McCracken,Andrew Wakeham,Jillian Haight,(unknown),Bryan E. Snow,Takeshi Ueda,Satoshi Inoue,Kazuo Yamamoto,Myunggon Ko,Anjana Rao,Katharine Yen,Shinsan M. Su,Tak W. Mak	224
10	Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutationsbreakdown → 2010 ·The Journal of Experimental Medicine ·Stefan Größ,Rob A. Cairns,Mark D. Minden,Edward M. Driggers,Mark Bittinger,Hyun Gyung Jang,Masato Sasaki,Shengfang Jin,David P. Schenkein,Shinsan M. Su,Lenny Dang,Valeria R. Fantin,Tak W. Mak	558
11	The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutaratebreakdown → 2010 ·Cancer Cell ·Patrick S. Ward,Jay Patel,David R. Wise,Omar Abdel‐Wahab,Bryson D. Bennett,Hilary A. Coller,Justin R. Cross,Valeria R. Fantin,Cyrus V. Hedvat,Alexander E. Perl,Joshua D. Rabinowitz,Martin Carroll,Shinsan M. Su,Kim A. Sharp,Ross L. Levine,Craig B. Thompson	1483
12	IDH mutations in glioma and acute myeloid leukemia 2010 ·Trends in Molecular Medicine ·Lenny Dang,Shengfang Jin,Shinsan M. Su	275
13	Cancer-associated IDH mutations: biomarker and therapeutic opportunities 2010 ·Oncogene ·Katharine Yen,(unknown),Shinsan M. Su,Valeria R. Fantin	227
14	Abstract 33: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate 2010 ·Cancer Research ·Valeria R. Fantin,Lenny Dang,David W. White,Stefan Größ,Mark Bittinger,Edward M. Driggers,Hyun Gyung Jang,Shengfang Jin,Marie C. Keenan,Kevin M. Marks,Katharine Yen,Patrick S. Ward,Robert M. Prins,Linda M. Liau,Bryson D. Bennett,Joshua D. Rabinowitz,Lewis C. Cantley,Craig B. Thompson,Matthew G. Vander Heiden,Shinsan M. Su	4
15	Cancer-associated IDH1 mutations produce 2-hydroxyglutarate 2010 ·Nature ·Lenny Dang,David W. White,Stefan Größ,Bryson D. Bennett,Mark Bittinger,Edward M. Driggers,Valeria R. Fantin,Hyun Gyung Jang,Shengfang Jin,Marie C. Keenan,Kevin M. Marks,Robert M. Prins,Patrick S. Ward,Katharine Yen,Linda M. Liau,Joshua D. Rabinowitz,Lewis C. Cantley,Craig B. Thompson,Matthew G. Vander Heiden,Shinsan M. Su	399
16	Cancer-associated IDH1 mutations produce 2-hydroxyglutaratebreakdown → 2009 ·Nature ·Lenny Dang,David W. White,Stefan Größ,Bryson D. Bennett,Mark Bittinger,Edward M. Driggers,Valeria R. Fantin,Hyun Gyung Jang,Shengfang Jin,Marie C. Keenan,Kevin M. Marks,Robert M. Prins,Patrick S. Ward,Katharine Yen,Linda M. Liau,Joshua D. Rabinowitz,Lewis C. Cantley,Craig B. Thompson,Matthew G. Vander Heiden,Shinsan M. Su	3067

About Shinsan M. Su

Shinsan M. Su is a scholar working on Cancer Research, Genetics and Hematology, having authored 16 papers that have together received 6.9k indexed citations. Recurring topics across this work include Cancer, Hypoxia, and Metabolism (11 papers), Glioma Diagnosis and Treatment (9 papers) and Epigenetics and DNA Methylation (6 papers). The work is most often cited by research in Cancer Research (3.5k citations), Genetics (2.4k citations) and Hematology (1.4k citations). Shinsan M. Su has collaborated with scholars based in United States, Canada and China. Frequent co-authors include Lenny Dang, Valeria R. Fantin, Shengfang Jin, Katharine Yen, Patrick S. Ward, Joshua D. Rabinowitz, Bryson D. Bennett, Craig B. Thompson, Stefan Größ and Edward M. Driggers. Their work appears in journals such as Nature, The Journal of Experimental Medicine and Genes & Development.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact